Cardiothoracic & vascular anesthesia
Levosimendan in Patients with Low Cardiac Output Syndrome After Cardiac Surgery: A Substudy of the Multicenter Randomized CHEETAH Trial
Authors' conclusion
Among patients requiring hemodynamic support after cardiac surgery with CPB, perioperative levosimendan infusion did not affect long-term survival (1-5 years) compared with placebo.
Study context
- Population
- Adults requiring hemodynamic support for cardiac index <2.5 L/min/m² after cardiac surgery with cardiopulmonary bypass (CPB), tertiary hospital
- Participants
- 134 adults
- Comparison
- Levosimendan vs placebo, in addition to standard inotropic care
- Primary endpoint
- Long-term mortality (1-5 years) after randomisation
- Follow-up
- 5 years
Methodological detailssingle-centre subanalysis, multicentre randomised trial, placebo-controlled
- Single-centre subanalysis
- Multicentre randomised trial
- Placebo-controlled
Primary result
As reported in the abstract
Long-term mortality (5 years) · 1-5 years
No significant between-group difference in long-term mortality (5 years)
HR 1.59; 95% CI 0.81 to 3.11
p = 0.17
Secondary outcomes
Mean pulmonary artery pressure · 4 to 6 hours after randomisation · lower with levosimendan
P = 0.019
Other secondary outcomes (hemodynamics, inotropic support, acute kidney injury (AKI), RRT, mechanical ventilation duration, intensive care unit (ICU) and hospital stay, 30-day mortality)
- No significant differences
Original publication
Levosimendan in Patients with Low Cardiac Output Syndrome After Cardiac Surgery: A Substudy of the Multicenter Randomized CHEETAH Trial. J Cardiothorac Vasc Anesth. Published 10 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →